Carl Zeiss Meditec AG (XSWX:AFX) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
70 GF Score
Price CHF26.30
GF Value CHF67.67
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Short-term investments?

Short-term investments only applies to insurance companies.

XSWX:AFX
70GF Score
Carl Zeiss Meditec AG XSWX:AFX
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF26.30 is trading 61.1% below its estimated GF Value™ of CHF67.67. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for XSWX:AFX:

  • Short-term investments:
  • GF Value™: CHF67.67 vs. price of CHF26.30 (61.1% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
70GF Score

Get the complete analysis for XSWX:AFX

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.30
Price
CHF67.67
GF Value